IRIS Accounts Production v24.3.0.553 10862889 director 1.4.23 31.3.24 31.3.24 false true false false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh108628892023-03-31108628892024-03-31108628892023-04-012024-03-31108628892022-03-31108628892022-04-012023-03-31108628892023-03-3110862889ns15:EnglandWales2023-04-012024-03-3110862889ns14:PoundSterling2023-04-012024-03-3110862889ns10:Director12023-04-012024-03-3110862889ns10:PrivateLimitedCompanyLtd2023-04-012024-03-3110862889ns10:SmallEntities2023-04-012024-03-3110862889ns10:AuditExempt-NoAccountantsReport2023-04-012024-03-3110862889ns10:SmallCompaniesRegimeForDirectorsReport2023-04-012024-03-3110862889ns10:SmallCompaniesRegimeForAccounts2023-04-012024-03-3110862889ns10:FullAccounts2023-04-012024-03-311086288912023-04-012024-03-3110862889ns10:RegisteredOffice2023-04-012024-03-3110862889ns5:CurrentFinancialInstruments2024-03-3110862889ns5:CurrentFinancialInstruments2023-03-3110862889ns5:Non-currentFinancialInstruments2024-03-3110862889ns5:Non-currentFinancialInstruments2023-03-3110862889ns5:ShareCapital2024-03-3110862889ns5:ShareCapital2023-03-3110862889ns5:RetainedEarningsAccumulatedLosses2024-03-3110862889ns5:RetainedEarningsAccumulatedLosses2023-03-3110862889ns5:NetGoodwill2023-04-012024-03-3110862889ns5:IntangibleAssetsOtherThanGoodwill2023-04-012024-03-3110862889ns5:PlantMachinery2023-04-012024-03-3110862889ns5:FurnitureFittings2023-04-012024-03-3110862889ns5:ComputerEquipment2023-04-012024-03-3110862889ns5:NetGoodwill2023-03-3110862889ns5:NetGoodwill2024-03-3110862889ns5:NetGoodwill2023-03-3110862889ns5:PlantMachinery2023-03-3110862889ns5:FurnitureFittings2023-03-3110862889ns5:ComputerEquipment2023-03-3110862889ns5:PlantMachinery2024-03-3110862889ns5:FurnitureFittings2024-03-3110862889ns5:ComputerEquipment2024-03-3110862889ns5:PlantMachinery2023-03-3110862889ns5:FurnitureFittings2023-03-3110862889ns5:ComputerEquipment2023-03-3110862889ns5:WithinOneYearns5:CurrentFinancialInstruments2024-03-3110862889ns5:WithinOneYearns5:CurrentFinancialInstruments2023-03-3110862889ns5:Secured2024-03-3110862889ns5:Secured2023-03-3110862889ns5:DeferredTaxation2023-03-3110862889ns5:DeferredTaxation2023-04-012024-03-3110862889ns5:DeferredTaxation2024-03-31
REGISTERED NUMBER: 10862889 (England and Wales)















Unaudited Financial Statements for the Year Ended 31 March 2024

for

R&S PHARMA LIMITED

R&S PHARMA LIMITED (REGISTERED NUMBER: 10862889)

Contents of the Financial Statements
FOR THE YEAR ENDED 31 MARCH 2024










Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 4


R&S PHARMA LIMITED

Company Information
FOR THE YEAR ENDED 31 MARCH 2024







DIRECTOR: Mrs Shivali Patel





REGISTERED OFFICE: 293 Green Lanes
Palmers Green
London
N13 4XS





REGISTERED NUMBER: 10862889 (England and Wales)





ACCOUNTANTS: ADPL LLP
293 Green Lanes
London
N13 4XS

R&S PHARMA LIMITED (REGISTERED NUMBER: 10862889)

Balance Sheet
31 MARCH 2024

31.3.24 31.3.23
Notes £    £    £    £   
FIXED ASSETS
Intangible assets 4 352,000 366,667
Tangible assets 5 18,895 23,620
370,895 390,287

CURRENT ASSETS
Stocks 54,310 56,935
Debtors 6 50,903 53,548
Cash at bank and in hand 68,892 151,669
174,105 262,152
CREDITORS
Amounts falling due within one year 7 134,826 138,089
NET CURRENT ASSETS 39,279 124,063
TOTAL ASSETS LESS CURRENT
LIABILITIES

410,174

514,350

CREDITORS
Amounts falling due after more than one
year

8

(337,664

)

(444,611

)

PROVISIONS FOR LIABILITIES 10 (3,590 ) (4,488 )
NET ASSETS 68,920 65,251

CAPITAL AND RESERVES
Called up share capital 1,000 1,000
Retained earnings 67,920 64,251
SHAREHOLDERS' FUNDS 68,920 65,251

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 March 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 March 2024 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges her responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

R&S PHARMA LIMITED (REGISTERED NUMBER: 10862889)

Balance Sheet - continued
31 MARCH 2024


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the director and authorised for issue on 15 November 2024 and were signed by:





Mrs Shivali Patel - Director


R&S PHARMA LIMITED (REGISTERED NUMBER: 10862889)

Notes to the Financial Statements
FOR THE YEAR ENDED 31 MARCH 2024


1. STATUTORY INFORMATION

R&S Pharma Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

In carrying out this assessment, the directors have considered the impact of the Covid-19 pandemic on the trade and finances of the company and wider group and they have taken steps to protect liquidity.

The directors are therefore satisfied that there is no significant risk to the ability of the company to continue as a going concern for at least 12 months from the date of approval of these financial statements.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Goodwill
Goodwill, being the amount paid in connection with the acquisition of a business in 2018, is being amortised evenly over its estimated useful life of thirty years.

Intangible assets
Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Plant and machinery - 20% on reducing balance
Fixtures and fittings - 20% on reducing balance
Computer equipment - 20% on reducing balance

Stocks
Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.


R&S PHARMA LIMITED (REGISTERED NUMBER: 10862889)

Notes to the Financial Statements - continued
FOR THE YEAR ENDED 31 MARCH 2024


2. ACCOUNTING POLICIES - continued
Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 4 (2023 - 5 ) .

4. INTANGIBLE FIXED ASSETS
Goodwill
£   
COST
At 1 April 2023
and 31 March 2024 440,000
AMORTISATION
At 1 April 2023 73,333
Charge for year 14,667
At 31 March 2024 88,000
NET BOOK VALUE
At 31 March 2024 352,000
At 31 March 2023 366,667

R&S PHARMA LIMITED (REGISTERED NUMBER: 10862889)

Notes to the Financial Statements - continued
FOR THE YEAR ENDED 31 MARCH 2024


5. TANGIBLE FIXED ASSETS
Fixtures
Plant and and Computer
machinery fittings equipment Totals
£    £    £    £   
COST
At 1 April 2023
and 31 March 2024 4,988 44,855 8,034 57,877
DEPRECIATION
At 1 April 2023 1,585 29,545 3,127 34,257
Charge for year 681 3,062 982 4,725
At 31 March 2024 2,266 32,607 4,109 38,982
NET BOOK VALUE
At 31 March 2024 2,722 12,248 3,925 18,895
At 31 March 2023 3,403 15,310 4,907 23,620

6. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
31.3.24 31.3.23
£    £   
Trade debtors 45,473 44,672
Other debtors 5,430 8,876
50,903 53,548

7. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
31.3.24 31.3.23
£    £   
Bank loans and overdrafts 52,289 52,289
Trade creditors 58,301 59,653
Taxation and social security 12,565 19,798
Other creditors 11,671 6,349
134,826 138,089

8. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE
YEAR
31.3.24 31.3.23
£    £   
Bank loans 195,663 262,610
Other creditors 142,001 182,001
337,664 444,611

Amounts falling due in more than five years:

Repayable by instalments
Bank loans more 5 yr by instal 49,933 116,880

R&S PHARMA LIMITED (REGISTERED NUMBER: 10862889)

Notes to the Financial Statements - continued
FOR THE YEAR ENDED 31 MARCH 2024


9. SECURED DEBTS

The following secured debts are included within creditors:

31.3.24 31.3.23
£    £   
Bank loans 247,952 314,899

10. PROVISIONS FOR LIABILITIES
31.3.24 31.3.23
£    £   
Deferred tax 3,590 4,488

Deferred
tax
£   
Balance at 1 April 2023 4,488
Credit to Income Statement during year (898 )
Balance at 31 March 2024 3,590